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Abstract Introduction: Postmortem studies suggest that fibrillar brain amyloid places people at higher risk for
hazardous driving in the preclinical stage of Alzheimer’s disease (AD).
Methods: We administered driving questionnaires to 104 older drivers (19 AD, 24 mild cognitive
impairment, and 61 cognitive normal) who had a recent 18F-florbetapir positron emission tomography
scan. We examined associations of amyloid standardized uptake value ratios with driving behaviors:
traffic violations or accidents in the past 3 years.
Results: The frequency of violations or accidents was curvilinear with respect to standardized uptake
value ratios, peaking around a value of 1.1 (model r2 5 0.10, P 5 .002); moreover, this relationship
was evident for the cognitively normal participants.
Discussion: We found that driving risk is strongly related to accumulating amyloid on positron emis-
sion tomography, and that this trend is evident in the preclinical stage of AD. Brain amyloid burden
may in part explain the increased crash risk reported in older adults.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: Alzheimer’s disease; Cognitive aging; Assessment of cognitive disorders; Dementia; MCI (mild cognitive impair-
ment); Biomarkers; Driving
1. Introduction
Postmortem studies of the brains of older drivers who
were killed in motor vehicle accidents (MVAs) have found
that many had the neuropathologic changes of Alzheimer’s
disease (AD), although they may have never been diagnosed
to have the disease [1–4]. Since then, advances in biomarker
technology have fostered new research criteria for the
“preclinical” stage of AD [5] preceding the intermediate
stage of mild cognitive impairment (MCI) or “prodromal”
AD [6], during which time amyloid pathology may be pre-
sent before any noticeable symptoms of cognitive or func-
tional impairments exist. These criteria are leading to an
increasing body of knowledge about the very earliest signs
and symptoms of AD as well as an impetus to identify sen-
sitive clinical markers of underlying AD pathology such as
amyloid plaque deposition.
Abnormal levels of AD biomarkers using the Pittsburgh
compound amyloid positron emission tomography (PET)
ligand were recently reported to predict performance on a
standardized road test by cognitively normal older individ-
uals, raising concern that amyloid deposition during the pre-
clinical phase of AD could indicate an increased risk for
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hazardous driving [7]. Therefore, we examined whether the
presence of increased amyloid on PET places an older person
at risk for unsafe driving as evidenced by actual traffic viola-
tions or MVAs in the preclinical and the symptomatic stages
of the disease. Because recent models of AD pathophysiology
suggest that amyloid pathology rises during the preclinical
stage and then plateaus in the symptomatic stage [8], we hy-
pothesized that this relationship, if it exists, may be more
evident in preclinical disease than in AD or MCI.
2. Methods
2.1. Standard protocol approvals, registrations, and
patient consents
The institutional review board of Rhode Island Hospital
approved the research protocol, and all participants or their
legally authorized representative provided informed consent
to participate.
2.2. Study design and participants
We selected a convenience sample of people attending an
outpatient memory clinic and included 19 AD, 24 MCI, and
61 cognitively normal elders. Inclusion criteria included
attendance to the memory clinic and amyloid PET done as
part of other observational or clinical trial research studies
within the past 6 months. Clinical diagnoses of AD [9] and
MCI [6] were made by a neurologist based on research
criteria of the National Institute on Aging and the Alz-
heimer’s Association. Cognitively normal elders all had a
Clinical Dementia Rating [10] of 0 (see Table 1). The age
range for participants was 51 to 85 years, standardized up-
take value ratio (SUVR) range was 0.7 to 1.8, driving avoid-
ance range of ratings was 1 to 5, and the number of miles
driven per week range was 5 to 600.
2.3. Driving behavior
We administered a driving questionnaire, developed by
the American Academy of Neurology as part of its most
recent practice parameter on driving and dementia [11].
Questionnaire versions are available for drivers and family
informants. The questionnaire includes three initial ques-
tions: (1) “How many times have you been stopped or tick-
eted for a traffic violation in the last three years?” (2) “How
many accidents have you been in, or caused, within the last
three years?” and (3) “In how many accidents were you at
fault in the last three years?” The answers were circled on
paper with the choices being 1, 2, 3, or 4 or more. We defined
a positive response to any violation or accident in the past
3 years from the participant or their family informant as
our primary outcome measure (see Table 2). Ten additional
questions were about current driving behaviors that were
generally regarded as risk factors for MVAs. These were
anchored by a 5-point Likert scale ranging from “strongly
disagree” to “strongly agree.” We defined a driving avoid-
ance outcome variable as the mean across four of these
items: limited amount of time driving, avoiding driving at
night, avoiding driving in the rain, and avoiding driving in
busy traffic. We used the maximum of the mean rating
from driver and family informant in analytic models. Finally,
Table 1











Women 69 (66) 43 (71) 13 (54) 13 (68)
Men 35 (34) 18 (30) 11 (46) 6 (32)
Age [M (SD)] 67 (8) 64 (7) 72 (8) 68 (11)
SUVR [M (SD)] 1.1 (0.3) 1.0 (0.2) 1.2 (0.3) 1.3 (0.3)
SUVR class [N (%)]
,1.1; Negative 64 (62) 49 (80) 9 (38) 6 (32)
1.1–1.2; Intermediate 5 (5) 3 (5) 1 (4) 1 (5)
.1.2; Positive 35 (34) 9 (15) 14 (58) 12 (63)
Consensus reading [N (%)]
Negative 68 (65) 50 (82) 11 (46) 7 (37)
Positive 36 (35) 11 (18) 13 (54) 12 (63)
No violation or accident
In past 3 years [N (%)] 70 (67) 38 (62) 17 (71) 15 (79)
Any violation or accident
In past 3 years [N (%)] 34 (33) 23 (38) 7 (29) 4 (21)
Accident, family report 21 (20) 11 (21) 6 (26) 4 (21)
Violation, self report 17 (16) 14 (23) 2 (9) 1 (6)
Accident, self-report 17 (16) 11 (18) 4 (17) 2 (12)
Violation, family report 9 (9) 6 (11) 2 (9) 1 (5)
Driving avoidance [M (SD)]
Self-report 1.5 (0.8) 1.4 (0.8) 1.5 (0.9) 1.7 (1.0)
Family report 1.7 (0.9) 1.4 (0.8) 1.9 (1.1) 2.3 (0.9)
Miles driven per
week [M (SD)]
118 (111) 147 (119) 92 (104) 58 (49)
Abbreviations: M, mean; MCI, mild cognitive impairment; SD, standard
deviation; SUVR, standard uptake value ratio.
NOTE. The mean of reports of limiting the amount of nighttime, rain, and
busy traffic driving are based on a scale of 1 (strongly agree) to 5 (strongly
disagree).
Table 2
Association of standard uptake value ratio (SUVR) and driving behavior




Any violation or accident 0.56* 20.57 y 0.38
Miles driven 20.07 0.02 0.22
Driving avoidance ratings 0.13 20.29 y 0.20
NOTE. Table entries are standardized regression coefficients (on the scale
of correlation coefficients) describing the linear relationship of driving
behavior and SUVR within two regions of SUVR. The model includes
adjustment for age, sex, and diagnostic group. Driving avoidance ratings
refer to the maximum of self- and family-reported mean ratings on four
driving avoidance patterns (amount, nighttime, rain, and busy traffic). Items
are rated on a 1 to 5 scale, where higher ratings indicate greater agreement
with avoidance patterns. A negative coefficient between SUVR and driving
avoidance ratings implies that the more Alzheimer’s disease–like amyloid
burden, driving avoidance behaviors are less or fewer.
*P , .01.
yP , .05.
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at the end of the questionnaire, the respondent was asked
“How many miles a week do you drive?” and we used this
response as an outcome variable for driving avoidance.
The driver and a family member informant each completed
the questionnaire independently without knowledge of the
other’s responses.
2.4. Ab PET imaging
The radiotracer 18F-florbetapir was used in all studies. A
370-MBq (10 mCi) bolus injection of F-18 florbetapir was
administered intravenously. Approximately 50 minutes after
injection, a 20-minute PET scan was performed with head
computed tomography (CT) scan for attenuation correction
purposes. The scans were all performed on a Philips Gemini
GXL 16 PET/CTwith the CT scan performed for attenuation
purposes. PET standardized uptake value (SUV) data for six
regions in the cerebral cortex were summed and normalized
to the whole cerebellum SUV, resulting in a cerebral cortex-
to-cerebellum ratio termed SUVR. This calculation was per-
formed using MIMneuro software [12]. We used an SUVR
threshold of 1.2 or greater to discriminate betweenAb positive
and negative, as recommended previously to indicate the pres-
ence of moderate to frequent amyloid plaques [13,14]. SUVR
of 1.1 to 1.2 was regarded as intermediate positivity based on a
previous report showing that SUVR of 1.08 to 21.17
represents an intermediate band representing the presence of
any amount of amyloid deposits [15]. Ab positivity was also
determined by consensus qualitative visual reading by two
board-certified radiologists specializing in nuclear medicine.
2.5. Statistical analysis
We evaluated nonlinear trends in the relationship between
driving behaviors and SUVR using two-degree fractional
polynomial functions [16]. Logistic regression was used
for the binary accidents or violations’ outcome, linear
regression was used for driving avoidance and miles driven
models. Fractional polynomial model parameter estimates
were obtained with Stata software (version 14.1; Stata Cor-
poration, College Station, TX). Multivariate models were
estimated with Mplus software (version 7.4; Muthen &
Muthen, Los Angeles, CA).
3. Results
Participant characteristics are shown in Table 1.
Consensus reading by visual interpretation yielded 68 nega-
tive scans and 36 positive scans. Classification by SUVR
yielded 64 negative scans and 35 positive scans, with the
mean SUVR of 1.1 and range 0.7 to 1.8. Seventeen subjects
self-reported being ticketed and 17 subjects self-reported be-
ing in an MVA in the past 3 years, whereas family member
reports for the same items were 9 and 21, respectively. For
descriptive analyses we used a composite outcome that rep-
resents the occurrence of any violation orMVA by either self
or family member report. This composite variable defined 70
negatively involved subjects, that is, no retrospective history
of recent adverse driving events, and 34 positively involved
subjects. The average reported number of miles driven per
week was 118 6 111 (range 5–600).
To assess the safety index of drivers in each subgroup,
we examined the number of reported accidents per reported
miles driven. The mean (standard error) number of
accidents per 1000 miles driven was 2.5 (2.4), 9.5 (3.6),
and 9.2 (4.0) for the normal, MCI, and dementia groups,
respectively.
We found a nonlinear relationship between the risk of a
violation or MVA (either from self or family member report)
and average SUVR as determined from a fractional polyno-
mial model. At an SUVR of about less than 1.1, risk for vio-
lations or accidents increased linearly with increasing
amyloid. The model using just nonlinear functions of
SUVR to account for the occurrence of violations or accidents
has a pseudo-r2 of 0.10 and is highly significant versus a null
model (P 5 .002). Using multivariate regression, we deter-
mined that at an SUVR level of less than 1.1, the biserial cor-
relation of SUVR and violations or accidents was r 5 0.56
(P5 .007). At an SUVR of about greater than 1.1, risk for vi-
olations or accidents decreased with increasing SUVR
(r 5 20.57, P 5 .014).
The nonlinear relationship was similar across the diag-
nostic group and is illustrated for the cognitively normal sub-
group and the MCI or dementia subgroups in Fig. 1. Because
of the low frequency of events, the relationship between
SUVR and violations or accidents in the normal subgroup
was relatively flat across the confidence levels beyond an
SUVR of 1.1 and not statistically significant. In post hoc
analysis, we tested for possible modification of the effect
of SUVR in prior violations or accidents. We accomplished
this using a multivariable logistic regression model, the frac-
tional polynomial terms for SUVR, and their interaction
with the diagnostic group. We found no evidence
(P 5 .24) that the nonlinear relationship between SUVR
and the frequency of violations or accidents varies across
the diagnostic group, including statistical adjustment for
age, sex, and the main effect of diagnostic group.
The optimally fitting two-degree fractional polynomial
function for the relationship of driving avoidance and
SUVR suggested a curvilinear pattern as seen with viola-
tions or accidents, and for driving avoidance neither a simple
linear nor a curvilinear model fit better than a null model (P
values .52 and .86, respectively). Thus, these data cannot be
used to support a meaningful relationship between driving
avoidance and SUVR. The optimally fitting two-degree frac-
tional polynomial function for the relationship of miles
driven and SUVR suggested a curvilinear pattern as seen
with violations or accidents, and although a simple linear
model was significant (P 5 .04), an optimally fitting two-
degree fractional polynomial offered no additional signifi-
cant improvement in fit (P 5 .70).
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3.1. Multivariate models
We used multivariate piecewise regression modeling to es-
timate general trends in driving behavior outcomes as a func-
tion of SUVR. We used a piecewise effect for SUVR,
estimating one linear slope for SUVR values increasing up
to 1.1, and a second linear slope from values 1.1 and higher.
Models included statistical adjustment for the effects of
age, sex, and diagnostic group. Results are summarized in
Table 2 in the form of standardized regression coefficients,
which are on the scale of correlation coefficients and useful
effect size measures. Results show large effects of SUVR in
the propensity to have had any violation or accident,
increasing with increasing SUVR less than 1.1 (r 5 0.56,
P 5 .007) and decreasing greater than 1.1 (r 5 0.57,
P 5 .01). Driving avoidance behaviors were slightly posi-
tively (r 5 0.13, P 5 .26) correlated with increasing SUVR
if SUVR was less than 1.1, and moderately inversely corre-
lated with SUVR greater than 1.1 (r 5 20.29, P 5 .03).
That is, after controlling for age and sex and diagnostic group,
SUVR values greater than 1.1 were associated with less or
fewer driving avoidance behaviors. Miles driven was essen-
tially uncorrelated with SUVR values both less than 1.1
(r520.07, P5 .68) and greater than 1.1 (r5 0.02, P5 .86).
In the samemultivariate models estimated and reported in
Table 2, we also included dummy variables for the diag-
nostic group. The results of the baseline complete sample
standardized mean differences (d) for MCI and dementia
groups for each of the driving behavior outcomes are sum-
marized in Table 3. Here, we see that although the diagnostic
group does not relate significantly to risk of accidents or vi-
olations for more than the past 3 years (however, MCI partic-
ipants have a slightly increased propensity [d 5 0.11,
P5 .70] and dementia participants a slightly diminished pro-
pensity [d 5 20.17, P 5 .64]), we see strong relationships
between the diagnostic group and driving behavior out-
comes. Relative to cognitive normal participants, those
with MCI had moderately lower mean miles driven
(d520.65, P5 .01) and more driving avoidance behaviors
(d5 0.62, P5 .006). Also relative to cognitively normal par-
ticipants, those with dementia had large effects in terms of
miles driven (d521.1, P, .001) and driving avoidance be-
haviors (d 5 1.2, P , .001).
4. Discussion
The decline in driving ability among older adults may be
associated with multiple age-related phenomena, including
changes in vision, motor function, and reaction time, as
well as comorbid conditions such as cataracts, sleep apnea,
arthritis, medication adverse effects, metabolic disorders
[17,18], and cognitive changes because of AD [19]. The
Table 3
Effect size for difference in mean driving outcomes relative to control
subjects for mild cognitive impairment (MCI) and dementia groups
Driving behavior MCI Dementia
Any violation or accident 0.11 20.17
Miles driven 20.65* 21.07y
Driving avoidance ratings 0.62z 1.17y
NOTE. Table entries describe standardized mean differences in driving
outcome attributable to MCI or dementia group membership. Any violations
or accidents’ outcome is binary, and the standardizedmean difference refers to
the underlying latent response variable for violations or accidents. Driving
avoidance ratings refer to themaximum of self- and family-reportedmean rat-
ings on four driving avoidance patterns (amount, nighttime, rain, and busy
traffic). Items are rated on a 1 to 5 scale, where higher ratings indicate greater




Fig. 1. Relationship between the proportion of subjects in the cognitively normal group (left) and the MCI and dementia subgroup (right) with any violation or
accident and SUVR. The smoothed function is an estimated fractional polynomial logistic function and 95% confidence interval fit to the observed SUVR data.
The one-way distribution of SUVR within the group is illustrated with the rug at the bottom of the plot area. Abbreviations: MCI, mild cognitive impairment;
SUVR, standard uptake value ratio.
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observational data from our study based on retrospective
questionnaire information suggest that driving is an impor-
tant and highly complex daily living function that provides
a sensitive indicator of declining cognition and may be an
important safety consideration for older people who are in
the preclinical stage of AD [20].
Before discussing our results in the context of prior
research, it is important to acknowledge the limitations of
our research. Most importantly, our results derive from a
descriptive analysis of an observational cohort. We used a
retrospective collection of driving outcomes for more than
the past 3 years and were not able to examine those events
that occurred in a more temporally proximate time to the
PET scan, which reduces the strength of cause and effect in-
ferences. The significant effects we observe may be false pos-
itive research findings and require replication. This possibility
is exacerbated by a relatively small sample size, which has the
result of requiring effects larger thanmight be considered clin-
ically or practically relevant to infer statistical significance,
and also raises the possibility that detected effects represent
false positives. Another limitation is that our outcome data
on traffic incidents are based on self and proxy report.
Two large longitudinal driving studies of normal and
cognitively impaired elders have previously shown decre-
ments in driving performance on road test performance
even among control subjects with normal cognition at base-
line, raising important questions as to what may be the under-
lying cause or causes for such decline [21,22]. In a 2-year
longitudinal study of more than 1051 older adults, future
development of dementia was the only factor found to be
significantly associated with self-reported crashes at baseline,
and it was not associated with driving cessation [23].
Severity of driving impairment in people with AD has
been shown to correlate with cerebral blood flow changes
in the temporo-occipital regions in early stage disease and
with frontal deficits in more advanced impairment, particu-
larly in the right hemisphere, using single photon emission
CT [24]. Recent advances in PET now permit investigators
to examine brain behavior relationships with actual amyloid
brain deposits during life. Several studies have demonstrated
a significant correlation between amyloid PET results and
postmortem examinations [14,25–27]. Use of this
technology allows investigators to examine whether the
observations described in postmortem studies of older
drivers can be supported by studies of well-described living
people defined by standard diagnostic criteria who have been
involved in MVAs or traffic violations.
As we expected, a history of accidents and violations was
predictive of higher levels of amyloid deposition on PET im-
aging. This observation supports previous case reports and
postmortem series that found a higher than expected fre-
quency of AD pathology in older drivers who had died in
car MVAs [1–4]. Among 98 older drivers aged more than
64 years who died in MVAs, 33% had neuritic plaque
scores indicating probable AD and another 20% possible
AD [2,4]. A more recent postmortem study of 27 drivers
older than 64 years found that 52% of autopsied drivers
who died in an MVA had mild AD pathology compared
with 25% of control subjects who died of other causes.
None had a history of AD on medical records [1]. In a
detailed case report of a 75-year-old woman who died in
an MVA, she had no diagnosis of dementia before death,
but an interview with her son suggested that she may have
had MCI symptoms for 6 months before the MVA [3]. AD
pathology has also been described as a risk factor for older
pedestrians dying in traffic accidents [28,29]. Although
such research raises the intriguing possibility that driving
impairment in the elderly may signify a preclinical or
prodromal stage of AD, a major limitation of these
postmortem studies is that there is little if any information
regarding diagnosis, so some of these cases may have
actually had unrecognized dementia at the time of death.
We also found that moderation of driving behaviors that
might mitigate crash risk seems to be dependent on the pres-
ence of clinically manifest symptoms of cognitive impair-
ment and dementia, rather than solely on the presence of
increased amyloid levels in the brain. The attenuation of
driving behaviors and crash risk at high levels of SUVR
can be explained by moderation of driving behavior among
those with diagnosed MCI and AD dementia. Among those
in the preclinical stage of the disease, where cognitive defi-
cits are minimal or unrecognized as a clinical problem,
driving restriction probably does not occur, leaving those
with increasing amyloid burden in their brains exposed to
increased risk in more frequent and complex hazardous
driving situations. An illustration of this proposed model
of interaction among brain amyloid, driving exposure, and
accident occurrence is provided in Fig. 2.
Additional support for amyloid being a risk factor for
hazardous driving comes from our recent report showing
that amyloid biomarkers measured using Pittsburgh Com-
pound B with PET as well as cerebrospinal fluid (CSF) bio-
markers of amyloid were associated with impaired road test
performance in people with preclinical AD [7]. In this study,
Fig. 2. Conceptual diagram illustrating idealized relationships among
driving exposure, amyloid burden, and risks for violations or accidents as
a function of AD stage. Abbreviations: AD, Alzheimer’s disease; MCI,
mild cognitive impairment; SUVR, standard uptake value ratio.
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data from129 cognitively normal elders who had amyloid
PET (N 5 113) and/or CSF biomarker (N 5 123) found
that higher ratios of CSF tau/Ab42 and ptau181/Ab42, in addi-
tion to higher Pittsburgh compound B (PIB) mean cortical
binding potentials, were associated with increased number
of driving errors. Lower levels (the direction of biomarker
abnormality for CSFAb42) of CSFAb42 were also associated
with increases in the number of driving errors, but this did
not reach statistical significance (P5 .06), indicating overall
that cognitively normal older adults with more AD-like
biomarker values have worse driving performance.
Perhaps the most interesting and provocative finding in
our study is the clinical relevance of increasing levels of am-
yloid at levels less than what is typically considered indica-
tive of significant Alzheimer amyloid pathology. At this
level of SUVR there are sparse if any well-developed amy-
loid plaques, because florbetapir binds primarily if not solely
to fibrillar amyloid. However, at low levels of florbetapir
binding, more soluble Ab oligomers may still be present
and represent the more directly neurotoxic forms of the pro-
tein, as suggested by recent studies [30–33]. If this is the
case, further studies using radiologic ligands that tag more
soluble amyloid peptide species may yield more robust
associations with driving risk than the present study. Our
results also support a recent observation that many patients
with MCI experience cognitive and functional decline
associated with “prethreshold” levels of CSF Ab42 [34].
These results highlight how potentially important the
early recognition and accurate identification of preclinical
AD might be for personal and public safety. They also sug-
gest that clinically meaningful changes in function may
occur in the preclinical stage when amyloid burden in the
brain is lower than SUVR thresholds on PET typically felt
to indicate moderate to extensive amyloid pathology.
Future studies using larger sample sizes may be able to
focus solely on MVAs, as this is the major safety concern
for older drivers, who have an exceptionally high rate of
fatal car crashes compared with younger drivers because
of their frailty [35]. Also of note, one might expect that
a Stage III level of preclinical AD, as defined by the pres-
ence of cognitive impairment in addition to biomarkers of
disease [5], might be associated with higher levels of
driving risk. In this study, we did not have uniform psy-
chometric test scores available across participants to
enable such an analysis, but this would be an interesting
future focus of study.
In summary, the results from this retrospective observa-
tional study of older drivers suggest that driving problems in
the preclinical stage of ADmay be related to increasing levels
of amyloid deposition in the brain. If so, then assessment of
driving may provide important information about the effec-
tiveness of antiamyloid prevention therapies and their poten-
tial to improve the safety of older people who remain active
drivers. Prospective longitudinal research studies should
help to further clarify the magnitude of the safety risk posed
by amyloid deposits in the brains of older drivers.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional sources, including PubMed
search of relevant articles during the past 20 years.
There have been a small number of postmortem pub-
lications reporting a higher than expected prevalence
of Alzheimer pathology and two recent studies
examining epidemiologic and road test correlates in
preclinical Alzheimer’s disease.
2. Interpretation: Our findings provide additional sup-
port for these earlier observations, indicating that
driving impairment may be evident in older people
without apparent signs of cognitive decline although
they have accumulating Alzheimer pathology.
3. Future directions: The correlation between rising
levels of brain amyloid on positron emission tomog-
raphy with accidents and traffic violations at a stan-
dardized uptake value ratio level lower than that
typically associated with moderate to severe Alz-
heimer pathology suggests that lower standardized
uptake value ratio cutoff levels than currently being
used to define subjects for Alzheimer’s disease pre-
vention trials should be considered.
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